Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
Operating Cash Flow Growth TrendStable
Percentile Rank71
3Y CAGR-44.3%
5Y CAGR-13.9%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-44.3%/yr
Annual compound
5Y CAGR
-13.9%/yr
Recent deceleration
Percentile
P71
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineStable
| Period | Value |
|---|---|
| 2025 | 18.07% |
| 2024 | 19.16% |
| 2023 | -2797.45% |
| 2022 | 104.49% |
| 2021 | -19.28% |
| 2020 | 38.17% |
| 2019 | -3.45% |
| 2018 | -1.20% |
| 2017 | 27.90% |
| 2016 | 4.98% |